Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial

There is a paucity of evidence for dose and pace of up-titration of guideline-directed medical therapies after admission to hospital for acute heart failure. In this multinational, open-label, randomised, parallel-group trial (STRONG-HF), patients aged 18–85 years admitted to hospital with acute hea...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Lancet (British edition) 2022-12, Vol.400 (10367), p.1938-1952
Hauptverfasser:	Mebazaa, Alexandre, Davison, Beth, Chioncel, Ovidiu, Cohen-Solal, Alain, Diaz, Rafael, Filippatos, Gerasimos, Metra, Marco, Ponikowski, Piotr, Sliwa, Karen, Voors, Adriaan A, Edwards, Christopher, Novosadova, Maria, Takagi, Koji, Damasceno, Albertino, Saidu, Hadiza, Gayat, Etienne, Pang, Peter S, Celutkiene, Jelena, Cotter, Gad
Format:	Artikel
Sprache:	eng
Schlagworte:	Adverse events Angiotensin Blood pressure Brain natriuretic peptide Cardiology Cardiology and cardiovascular system Congestive heart failure Death Effectiveness Enzymes Female Health services Heart Failure Hospitals Human health and pathology Humans Laboratories Life Sciences Male Middle Aged Mineralocorticoid Receptor Antagonists - therapeutic use Minority & ethnic groups Missing data Mortality Patients Peptides Potassium Quality of Life Renin Risk Risk reduction Safety Stroke Volume Titration Treatment Outcome Ventricle Ventricular Function, Left
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!